Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

2.

Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

Sommet A, Grolleau S, Bagheri H, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centres.

Eur J Clin Pharmacol. 2008 Aug;64(8):829-34. doi: 10.1007/s00228-008-0497-3. Epub 2008 May 29.

PMID:
18509626
3.

Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E.

Drug Saf. 2012 Apr 1;35(4):315-23. doi: 10.2165/11596510-000000000-00000.

PMID:
22376166
4.

Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.

Curtis JR, Cheng H, Delzell E, Fram D, Kilgore M, Saag K, Yun H, Dumouchel W.

Med Care. 2008 Sep;46(9):969-75. doi: 10.1097/MLR.0b013e318179253b.

5.

Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database.

Wahab IA, Pratt NL, Ellett LK, Roughead EE.

Drug Saf. 2016 Apr;39(4):347-54. doi: 10.1007/s40264-015-0391-8.

PMID:
26798053
6.

Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Motola D, Vargiu A, Leone R, Conforti A, Moretti U, Vaccheri A, Velo G, Montanaro N.

Drug Saf. 2008;31(7):609-16.

PMID:
18558794
7.
8.

A computerized system for signal detection in spontaneous reporting system of Shanghai China.

Ye X, Fu Z, Wang H, Du W, Wang R, Sun Y, Gao Q, He J.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):154-8. doi: 10.1002/pds.1695.

PMID:
19115240
9.
10.

Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.

Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, Motola D, Salvo F, Rivolta AL, Blandizzi C, Mugelli A, Del Tacca M.

Drug Saf. 2008;31(12):1115-23. doi: 10.2165/0002018-200831120-00007.

PMID:
19026028
11.

A cross-country comparison of rivaroxaban spontaneous adverse event reports and concomitant medicine use with the potential to increase the risk of harm.

McDonald CJ, Kalisch Ellett LM, Barratt JD, Caughey GE.

Drug Saf. 2014 Dec;37(12):1029-35. doi: 10.1007/s40264-014-0235-y.

PMID:
25361529
12.

Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM.

Arch Intern Med. 2009 Nov 23;169(21):1976-85. doi: 10.1001/archinternmed.2009.394.

13.

Early detection of adverse drug events within population-based health networks: application of sequential testing methods.

Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R.

Pharmacoepidemiol Drug Saf. 2007 Dec;16(12):1275-84.

PMID:
17955500
14.

A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China.

Li C, Xia J, Deng J, Jiang J.

Pharmacoepidemiol Drug Saf. 2008 Jun;17(6):593-600. doi: 10.1002/pds.1601.

PMID:
18432629
15.

The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.

Clark RC, Maxwell SR, Kerr S, Cuthbert M, Buchanan D, Steinke D, Webb DJ, Bateman ND.

Drug Saf. 2007;30(4):357-66.

PMID:
17408312
16.

Observational studies and the withdrawal of rofecoxib.

Watson DJ, Santanello NC.

Pharmacoepidemiol Drug Saf. 2006 Mar;15(3):199-201; author reply 203-5. No abstract available.

PMID:
16508998
17.

Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.

Alvarez Y, Hidalgo A, Maignen F, Slattery J.

Drug Saf. 2010 Jun 1;33(6):475-87. doi: 10.2165/11534410-000000000-00000.

PMID:
20486730
18.

COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.

Durrieu G, Olivier P, Montastruc JL; French networks of Pharmacovigilance centers.

Eur J Clin Pharmacol. 2005 Sep;61(8):611-4. Epub 2005 Aug 24.

PMID:
16133552
19.

The Vioxx fallout.

Palmer K.

Minn Med. 2005 Mar;88(3):26-30. No abstract available.

PMID:
15852592
20.

Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.

Pacurariu AC, Straus SM, Trifirò G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma PM.

Drug Saf. 2015 Dec;38(12):1201-10. doi: 10.1007/s40264-015-0341-5.

Supplemental Content

Support Center